PIN51 Cost and Length of Stay Associated with Vancomycin-Induced Nephrotoxicity  by Stevens, V. et al.
 VA L U E  I N  H E A LT H  1 6  ( 2 0 1 3 )  A 3 2 3 – A 6 3 6  A349
transformed to common logarithms. Costs are stated in € (1€ = 25.5CZK). Results: 
A total 100 patients (about 10-15% of all HIV treated in the Czech Republic) were 
included. The mean age was 41.9 years (range 23-71), time since diagnosis 5.8 years 
(range 1-26), and period of assessment 30.5 months. Average total annual costs were 
highest for CD4+ <200 (22,905€ ; p<0.05) vs. CD4+ 200-499 (17,801€ ) and CD4+ >500 
(17,043€ ). HIV medication accounted for the majority of costs in all three subgroups 
(range 62% in CD4+ <200 to 88% in CD4+ >500). Patients with a disease duration of 
>10 years had highest annual costs of 22,841€ (p<0.05) compared to 15,783€ (dura-
tion 5-10 years) and 16,777€ (<5 years). HIV-medication accounted for the majority 
of costs here as well (from 70% to 88%; NS). In this analysis 17 % of costs in patients 
with disease duration of >10 years were due to hospitalization vs. 5 % in both other 
groups (NS). ConClusions: Similarly to published literature, we found highest 
costs in patients with low CD4+ lymphocytes and longer disease duration.
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objeCtives: Clostridium difficileinfection (CDI) is the leading cause of infectious 
diarrhoea in hospitalised patients. The majority of published burden of CDI stud-
ies refer to US or northern European populations. Knowledge of the burden of CDI 
on health care resource utilisation in Spain is limited. The aim of the study was to 
provide recent data on the burden of CDI in terms of hospital resources and costs 
and in particular attributable length of stay. Methods: A retrospective study was 
carried at a leading teaching hospital in Madrid. Data refer to sequential cases of 
CDI during the year 2011. Data were extracted from patient records using a prede-
fined structured protocol. Hospital onset CDI cases were matched at a ratio of two 
non-infected patients for each case to adjust for confounding variables. Results: 
A total of 44 CDI cases were identified of whom 25 were health care-associated 
and hospital-onset. The mean duration of diarrhoea (days) was 10.12+7.98. Using 
median regression, the attributable length of stay (LOS) due to CDI was 9.98+2.21 
days. The average number of isolation days was 9.21+8.27. The majority of patients 
were treated with oral metronidazole. The first episode cure rate was 83.7%, 30-day 
and overall mortality were 18.6 and 25.6% respectively, attributable mortality was 
4.65%. A total of 9.3% of patients experienced a recurrence occurring within 2-8 
weeks within hospital stay. The cost attributable to an individual case of CDI would 
be 4,331 euros, of which over 90% is associated with hospital LOS. ConClusions: 
Our results highlight the significant burden of CDI in a large Spanish hospital. These 
costs will only continue to rise as the incidence of CDI continues to increase. A major 
breakthrough in cost reduction of CDI would be an intervention or procedure that 
shortens hospital length of stay and/or reduces episode recurrence.
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objeCtives: Decreased susceptibility to vancomycin has led to recommendations for 
increased serum concentration targets for some infections, which has been shown 
to increase the risk of nephrotoxicity (NT). The objective of this study was to deter-
mine if vancomycin-induced nephrotoxicity has a significant impact on cost from the 
hospital perspective or on length of stay. Methods: A cost of illness study from the 
hospital perspective. We conducted a secondary analysis of a cohort of 398 randomly 
selected inpatients receiving vancomycin in a tertiary care hospital in Rochester, New 
York, USA. Total and variable costs were generated by hospital accountants using 
micro-costing methods. NT was defined as 0.5 or 50% or greater increase in serum 
creatinine from baseline. Generalized linear models with log link and gamma distribu-
tion and semi-log regression were used to model total and variable costs and length 
of stay, respectively. Cost estimates are reported in 2009 USD. Results: Forty-nine 
(12%) of patients had NT. The unadjusted median variable costs for patients with NT 
were higher than for patients without NT ($47,511 vs. $22,355, p< .0001). On multi-
variable analysis, variable costs were 18% greater for patients with NT compared to 
patients without, but this difference was not statistically significant. The median 
length of stay for patients with NT was two-fold greater than for patients without 
NT (22 vs. 11 days, unadjusted, p< .0001). After accounting for severity of illness 
and other factors, NT patients stayed on average 46% longer than non-nephrotoxic 
patients. ConClusions: Patients with NT have significantly increased length of 
stay relative to patients without NT. Further research is needed to confirm whether 
increased length of stay has a meaningful impact on costs. As vancomycin suscep-
tibility continues to decrease, higher doses of vancomycin may lead to an increased 
incidence of NT and an increase in resource utilization among these patients.
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objeCtives: The purpose of this study was to estimate the health care resource uti-
lization, more specifically resource utilization for management of the most common 
adverse events (AE) associated with current treatment of hepatitis C virus (HCV) infec-
tion, in a real life setting. Methods: A retrospective study of the Quebec provincial 
drug reimbursement program (RAMQ) was conducted using a random sample of 
patients who filed at least one script for an HCV medication (pegylated-interferon and 
ribavirin (Peg-Riba) +/-boceprevir or telaprevir) between January 2007 and December 
2012. Data on medical (excluding nurse visits) and pharmaceutical services were 
extracted from the RAMQ database. We report health care resources used during 
HCV treatment including outpatient physician’s visits and procedures, emergency 
inclusion criteria, and 42% were adherent. After adjusting for confounders, ART adher-
ence was associated with 29% and 31% reductions in non-pharmacy costs (p< 0.0001)), 
67% and 80% increases in total pharmacy costs (p< 0.0001), 43% and 49% reductions 
in hospitalizations (p< 0.0001), and 41% and 26% reductions in emergency depart-
ment visits (p< 0.0001), among commercially insured and Medicaid patients, respec-
tively. ConClusions: This study suggests that ART adherence among commercially 
insured and Medicaid HIV patients in the US may be suboptimal, and that adherence 
is associated with improved economic outcomes among these patients.
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objeCtives: To perform a systematic literature review of economic evidence for 
genotype 1 hepatitis C virus (HCV) treatments. Methods: Searches were per-
formed in MEDLINE, MEDLINE In-Process, EconLit, Embase, BIOSIS, and the Cochrane 
Library, to identify economic evaluations, cost/resource studies, and utility studies 
in patients with genotype 1 HCV. Searches were limited to articles published since 
2000. Additional searches were performed on the ISPOR conference and key Health 
Technology Assessment (HTA) websites. Results: The review identified 53 economic 
evaluations, 17 HTA documents, 57 cost/resource use studies, and 19 utility stud-
ies. The majority of economic evaluations were in interferon-containing regimens 
and were performed using lifetime horizon Markov models. Incremental cost-effec-
tiveness ratios ranged from $4,570.31 to $157,404.13, depending on patient severity, 
the treatment used and the duration of treatment. Boceprevir and telaprevir triple 
therapies were shown to be cost-effective compared with peginterferon and ribavirin 
alone. In the cost studies, total all-cause, annual costs for patients with HCV ranged 
from $3,236 to $85,081, depending on the patients’ disease status and whether they 
were currently receiving treatment. Indirect costs for HCV patients were reported less 
frequently, but they ranged from $1,424 to $10,316 per patient per year. Utilities for 
patients with HCV ranged from 0.24 for patients experiencing severe adverse events 
to 0.89 for patients in sustained virological response. Recent economic models tended 
to use utility data taken from previous models or HTA submissions. ConClusions: 
Numerous recent cost-effectiveness studies are available for HCV; however, many 
of the economic evaluations are based on previous models. There is a particular 
scarcity of updated country-specific utility data. As more treatment options become 
available, and more robust models are developed, enhanced utility and cost studies 
may be needed.
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objeCtives: Meningococcal disease (MD) is a rare, life-threatening infection most 
common in infants (age < 1 year), adolescents, and persons living in close quar-
ters. In this study, we documented trends in hospital costs, length of stay (LOS), 
and mortality associated with pediatric MD cases in the United States (US) from 
2000 to 2009. Methods: Data for pediatric (age ≤ 20 years) MD-related hospitaliza-
tions (discharges with ICD-9-CM 036.xx) from the 2000, 2003, 2006, and 2009 HCUP 
Kids’ Inpatient Databases (KID) were retrospectively analyzed. Charges were con-
verted to costs using a 0.5 cost-to-charge ratio. Weighted, nationally representa-
tive estimates of costs per admission (in 2012 US dollars), LOS, and case fatality 
rates were descriptively analyzed for each year. Results: By year, total (weighted) 
numbers of pediatric MD-related hospitalizations in the US were: 2000 (N= 1,680), 
2003 (N= 1,089), 2006 (N= 745), 2009 (N= 581). Mean [SD] LOS for these hospitaliza-
tions was 8.4 [12.9] days in 2000, which decreased modestly to 7.7 [9.6] and 7.9 
[8.3] days in 2003 and 2006, respectively, before a substantial increase to 9.3 [13.9] 
days in 2009. Mean [SD] cost per admission fluctuated accordingly, increasing from 
$25,739 [$60,929] in 2000 to $33,530 [$62,499] in 2009. Case fatality rates, however, 
remained relatively unchanged during the period, declining slightly from 4.7% in 
2000 to 4.3% in 2009, although a noticeable spike occurred in 2003 when 5.8% of 
cases died. ConClusions: MD in the US pediatric population is associated with 
high costs resulting from hospital stays that typical exceed 1 week. Our estimated 
case fatality rate (~5%), while high, is lower than the 10-15% fatality rate estimated 
by the US Centers for Disease Control, which includes estimates from all age groups 
combined (pediatrics and adults). In light of these findings, recent efforts to raise 
awareness of MD as a serious public health concern should be continued.
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objeCtives: To assess direct medical costs of HIV patients, based on CD4+ lym-
phocyte count and duration since diagnosis in the Czech setting. Methods: We 
analyzed retrospectively costs of HIV patients in a single center. The analyzed sam-
ple included patients with a disease history of 12 month and longer, who regularly 
visited the center. Resource use, derived from the hospital information system, 
included services delivered at the HIV center and other hospital wards. The ret-
rospective period covered up to 36 months; average annual costs were calculated. 
Resource use was analyzed separately for (a) groups of CD4+ count (<200; 200-499; 
≥ 500); (b) time since diagnosis (<5 years; 5-10 years; >10 years). For comparison, 
two-sided Student’s t-test was used; to achieve normal distribution, values were 
